Eli Lilly (NYSE:LLY) and development partner Pfizer (NYSE:PFE) announcethat a Phase 3 clinical trial evaluating tanezumab in patients with moderate-to-severe chronic low back pain demonstrated a statistically significant improvement in pain at week 16 compared to placebo at the 10 mg dose (the 5 mg dose failed to sufficiently separate from control).
Detailed results will be submitted for presentation at a future medical conference and for publication.
The candidate was successful in two earlier late-stage studies in patients with osteoarthritis pain. A study in patients with cancer pain due to bone metastases is ongoing.
Tanezumab is a humanized monoclonal antibody that inhibits (binds to) nerve growth factor (NGF), a regulator of pain processing and sensitivity.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.